logo
Plus   Neg
Share
Email

Stock Alert: Corvus Pharma Surges 111%; Study Initiated For COVID-19 Treatment

Shares of Corvus Pharmaceuticals, Inc. (CRVS) more than doubled on Tuesday morning after the clinical stage biopharmaceutical company said it commenced a Phase 1 clinical study testing a novel treatment for COVID-19.

CRVS is currently trading at $5.80, up $3.06 or 111.68%, on the Nasdaq.

Corvus announced that it has initiated an early-state study to investigate a novel immunotherapy approach for patients with COVID-19. The study is expected to enroll up to 30 patients at several sites in the United States.

The enrollment follows the FDA's review and acceptance of the company's investigational new drug application for the COVID-19 study.

Corvus is studying an agonistic (immunostimulatory) humanized monoclonal antibody, designated as CPI-006, which has demonstrated a potential new approach to immunotherapy of infectious diseases and cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Humana Inc. (HUM) reported second quarter adjusted earnings per share of $12.56 compared to $6.05, previous year. On average, 22 analysts polled by Thomson Reuters expected the company to report profit per share of $10.27, for the quarter. Analysts' estimates typically exclude special items. Second... H-E-B has issued an all-store recall for Blue Cheese Salmon Burgers citing the presence of an undeclared allergen, the U.S. Food and Drug Administration announced. The products contain wheat, a known allergen, which is not declared on the product label. Consumers with allergy or severe sensitivity to wheat may get serious or life-threatening allergic reaction if they consume these products. The U.S. Securities and Exchange Commission is investigating the circumstances around Eastman Kodak Co.'s (KODK) announcement of a $765 million government loan to make ingredients for Covid-19 drugs, the Wall Street Journal reported citing people familiar with the matter.
Follow RTT